康艾注射液联合化疗对非小细胞肺癌疗效的Meta分析  

Meta-analysis of the Effect of Kang'ai Injection Combined with Chemotherapy on Non-small Cell Lung Cancer

作　　者：郭玉娇[1] 袁红宇[1] 

机构地区：[1]南京医科大学第一附属医院,南京210029

出　　处：《中国药房》2012年第35期3350-3353,共4页China Pharmacy

摘　　要：目的:系统评价康艾注射液联合化疗治疗非小细胞肺癌的疗效和安全性。方法:按照循证医学的要求,计算机检索维普中文科技期刊全文数据库、中国期刊全文数据库和中国生物医学文献光盘数据库,全面收集1994-2011年国内发表的康艾注射液联合化疗治疗非小细胞肺癌临床随机对照试验(RCT),采用Cochrane协作网专用软件RevMan4.2进行Meta分析。结果:23项RCT纳入Meta分析,与对照组比较,康艾注射液联合化疗组的有效率[RR=1.66,95%CI(1.35,2.03)]、生存质量改善[RR=3.22,95%C(I2.55,4.06)]、临床症状改善[RR=4.24,95%C(I2.79,6.46)]、白细胞减少[RR=0.36,95%C(I0.29,0.46)]等差异有统计学意义。结论:基于现有临床证据,康艾注射液联合化疗治疗非小细胞肺癌有提高疗效、提高生存质量、减轻不良反应的作用。OBJECTIVE： To evaluate the efficacy and safety of Kang＇ ai injection combined with chemotherapy on non-small cell lung cancer systematically. METHODS： According to the requirements of evidence-based medicine, retrieved from VIP, CNKI and CBM. 23 domestic published RCTs about Kang＇ ai injection combined with chemotherapy on non-small cell lung cancer during 1994 - 2011 were retrieved and included in Meta-analysis. RevMan 4.2 （Review manager） software provided by Cochrane collaboration net was applied for data processing and statistical analysis. RESULTS： 23 studies were involved in Meta-analysis. Compared with the control group, the results of combined test of effective rate, quality of life, clinical symptoms and leucocytopenia were as follows： [RR= 1.66, 95% CI （1.35, 2.03）], [RR=3.22, 95% CI （2.55, 4.06）], [RR=4.24, 95% CI （2.79, 6.46）], [RR=0.36, 95% CI （0.29, 0.46）]. CONCLUSION： From the existing clinical evidences, Kang＇ ai injection combined with chemotherapy in the treatment of non-small cell lung cancer could enhance the treatment efficacy, improve the life quality of patients and alleviate the side effects of chemotherapy.

关 键 词：康艾注射液 非小细胞肺癌 META分析 

分 类 号：R97[医药卫生—药品]